STAT

NOVEMBER 6, 2023

SAN DIEGO — Ventyx Biosciences reported on Monday that it was ending development of an experimental drug for treating plaque psoriasis though it proved safe and moderately effective in a mid-stage trial. Within hours, the company’s stock tanked by more than 80%. Shares in Ventyx plummeted from $14.09 during after-hours trading.

114

114

STAT

DECEMBER 11, 2023

During 2022, drugmakers substantially raised prices on eight widely used medicines without any new clinical evidence to justify the increases, leading patients and health insurers in the U.S. to spend an additional $1.2 billion last year, according to a new report.

Insurance 141

Insurance 141

Drug Topics

JANUARY 20, 2023

Highly effective medications for severe disease are expensive and administered invasively, while the development of treatments for milder disease has lagged, a new review on psoriasis clinical trials concludes.

98

98

European Pharmaceutical Review

JANUARY 11, 2024

The biologic targets the p40 protein, which has key roles in treating immune-mediated diseases like Crohn’s disease, psoriasis as well as psoriatic arthritis, Alvotech highlighted. Uzpruvo is produced in Sp2/0 cells via perfusion, in the same way that the reference product Stelara is.

Immunization 105

Immunization 105

Pharmaceutical Technology

MARCH 18, 2024

Adalimumab biosimilar is under clinical development by Biocon and currently in Phase III for Plaque Psoriasis (Psoriasis Vulgaris).

40

40

European Pharmaceutical Review

MARCH 28, 2023

The European Commission (EC) has approved Sotyktu (deucravacitinib), a first-in-class, allosteric tyrosine kinase 2 (TYK2) inhibitor for adults with moderate-to-severe plaque psoriasis. Data that supported the approval EC’s approval was based on results from Bristol Myers Squibb’s Phase III POETYK PSO-1 and POETYK PSO-2 clinical trials.

Dosage 95

Dosage Immunization 95

Outsourcing Pharma

FEBRUARY 15, 2024

Artax Biopharma, a clinical-stage biotech company focused on transforming the treatment of autoimmune diseases, has dosed the first patient in its phase 2a trial evaluating oral, small molecule, AX-158 for the treatment of psoriasis.

59

59

Fierce Pharma

NOVEMBER 14, 2023

In the market, however, Vtama is struggling to catch on. As a result, Leerink Partners has slashed its sales projections for the nonsteroidal topical treatment.

97

97

Pharmacy Times

NOVEMBER 10, 2023

The sBLA was based on data from a clinical study assessing the pharmacokinetics of switching between adalimumab and adalimumab-bwwd for patients with moderate to severe plaque psoriasis.

FDA 65

FDA 65

Hospital Pharmacy Europe

APRIL 3, 2023

Psoriasis represents a chronic immune-mediated inflammatory skin disease with lesions characterised by hyper-proliferation of epidermal keratinocytes associated with inflammatory cellular infiltrate in both dermis and epidermis. Oral vitamin D supplementation and psoriasis disease severity A total of 122 participants with a mean age of 53.6

Immunization 98

Immunization Hospitals 98

Hospital Pharmacy Europe

JUNE 19, 2023

To date, there are two further PDE inhibitors available: apremilast, which is an established oral therapy for psoriasis, and crisaborole, a topical agent used to treat atopic eczema. Psoriasis management Topical roflumilast 0.3% has gained gained FDA approval for use in patients with plaque psoriasis.

FDA 98

FDA Hospitals 98

The Checkup by Singlecare

FEBRUARY 20, 2024

The need for better psoriasis treatments has been long-standing for years. Now, options for effective psoriasis relief have multiplied. Due to these recent developments, 8 million Americans and 30 million people worldwide with psoriasis have reason for optimism. It, too, got approval from the FDA in 2022.

FDA 52

FDA Immunization 52

pharmaphorum

FEBRUARY 1, 2021

It’s well recognised that people with psoriasis can develop depression or anxiety, particularly in moderate or severe cases where a sizeable part of the body can have skin lesions. It’s not the first time that Almirall has partnered with a digital health specialist to develop tools that complement its drug therapies for psoriasis.

124

124

European Pharmaceutical Review

DECEMBER 14, 2022

a wholly-owned subsidiary of Nimbus Therapeutics and Nimbus Therapeutics’ tyrosine kinase 2 (TYK2) inhibitor NDI-034858, an oral, potential best-in-class selective allosteric TYK2 inhibitor for multiple autoimmune diseases following successful recent Phase IIb results in psoriasis. For $4 billion , Takeda will acquire Nimbus Lakshmi, Inc.,

88

88

Pharmaceutical Technology

DECEMBER 20, 2023

Zasocitinib is under clinical development by Takeda Pharmaceutical and currently in Phase III for Plaque Psoriasis (Psoriasis Vulgaris).

40

40

European Pharmaceutical Review

JULY 4, 2023

JNJ-2113, the first and only oral interleukin-23 receptor (IL-23R) antagonist peptide in development for moderate-to-severe plaque psoriasis (PsO) has demonstrated positive results in a Phase II trial. How does Janssen’s oral IL-23R antagonist for plaque psoriasis work? at the World Congress of Dermatology 2023. .

77

77

Pharmaceutical Technology

DECEMBER 5, 2023

ONO-4685 is under clinical development by Ono Pharmaceutical and currently in Phase I for Plaque Psoriasis (Psoriasis Vulgaris).

40

40

Outsourcing Pharma

MARCH 24, 2022

The pharmaceutical company's clinical study is intended to examine critical gaps in care for people of color living with moderate to severe plaque psoriasis.

Pharmaceutical Companies 96

Pharmaceutical Companies Pharmaceutical Companies 96

The Checkup by Singlecare

FEBRUARY 27, 2024

For centuries, oatmeal has been used as a treatment for skin irritations like rashes, burns, insect bites, eczema, and psoriasis. How to make an oatmeal bath Dermatology nurse practitioner Sherry Sanvictores frequently recommends a colloidal oatmeal bath to her patients suffering from inflammatory skin conditions like eczema and psoriasis.

Compounding 83

Compounding 83

Pharmaceutical Technology

SEPTEMBER 12, 2022

The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb ’s (BMS) Sotyktu (deucravacitinib) to treat adult patients with moderate-to-severe plaque psoriasis. The approval is based on data from the Phase III POETYK PSO-1 and POETYK PSO-2 clinical trials.

FDA 98

FDA 98

The Checkup by Singlecare

NOVEMBER 17, 2023

Psoriasis Psoriasis is a long-term skin condition that causes scaly, itchy plaques on the skin. have psoriasis, according to the National Psoriasis Foundation. RELATED: Psoriasis vs. eczema vs. dry skin: How to tell the difference Stress and anxiety Sometimes, emotional distress can manifest physically.

Immunization 90

Immunization Medical Schools 90

pharmaphorum

OCTOBER 26, 2022

Psoriasis is a tricky disease to manage, as drawbacks and side effects loom with each and every type of treatment. Anyone who watches television has heard the list of potential adverse reactions, considering that commercials for psoriasis treatments are seemingly only outnumbered by goofy ads for auto insurance. Manage it early.

Immunization 98

Immunization Adverse Reactions Insurance FDA 98

STAT

MARCH 18, 2023

In an intermediate-stage clinical study of 259 people with moderate-to-severe plaque psoriasis, the highest dose of the daily pill completely cleared itchy and painful patches of skin in one-third of the patients after 12 weeks.

Immunization 107

Immunization 107

Outsourcing Pharma

MAY 26, 2023

The first patients with psoriasis have been dosed with a new drug to help combat the inflammatory skin disease in a clinical trial in China.

52

52

Pharmafile

APRIL 12, 2023

ALM) , a global biopharmaceutical company focused on skin health, today announced the publication in the British Medical Journal (BMJ) of the POSITIVE study protocol, the first clinical study in dermatology to assess patients’ wellbeing as a primary endpoint. April 12, 2023 – Almirall, S.A. read more

52

52

European Pharmaceutical Review

JUNE 29, 2023

This is relevant in Crohn’s disease, ulcerative colitis and chronic skin disease psoriasis. Previous research has shown that blocking interleukin-23 with specific therapeutic antibodies is very effective in psoriasis and Crohn’s disease. Mirikizumab is the first such antibody tested for ulcerative colitis. percent versus 13.3

92

92

STAT

AUGUST 7, 2023

” As a result, Lilly “botched” the analysis of early clinical trial data in which Rezpeg was tested as a treatment for eczema and psoriasis. Continue to STAT+ to read the full story…

91

91

PharmaShots

JANUARY 23, 2023

The specific mechanisms by which VTAMA cream exerts its therapeutic action in psoriasis patients are unknown. Until recently, there were very few topical options available for treating plaque psoriasis long-term. Smriti: Brief us about the study design of the P-III clinical trial evaluating VTAMA cream. of VTAMA cream?

FDA 40

FDA Labelling Immunization 40

Pharma Mirror

SEPTEMBER 16, 2022

Barcelon, a global biopharmaceutical company focused on skin health, announced at the 31st EADV (European Association of Dermatology and Venereology) Congress the results from TRIBUTE, an interventional phase IV clinical study, which resembled real-life clinical practice. In this study, Ilumetri®?

52

52

pharmaphorum

DECEMBER 22, 2021

Amgen has won FDA approval for a stronger label for its oral plaque psoriasis therapy Otezla, as it prepares for competition from Bristol-Myers Squibb’s much-touted rival deucravacitinib, which could make its debut next year. The post Amgen builds Otezla’s psoriasis label as rival BMS looms large appeared first on.

Labelling 58

Labelling FDA 58

PharmaShots

JUNE 22, 2023

in patients with HS The results showed a clinical improvement for patients who completed the planned 16wks. The results were consistent with the results from the P-IIb dose-finding study (IASOS) in psoriasis The results will be presented at an upcoming scientific conference. of treatment, improvements incl.

53

53

Pharmaceutical Technology

JULY 12, 2022

Health Canada has accepted to review Arcutis Biotherapeutics’ New Drug Submission (NDS) for roflumilast cream 0.3% (ARQ-151) to treat plaque psoriasis in adult and adolescent patients. The NDS submission by Arcutis is based on positive findings from the company’s pivotal Phase III programme and two long-term open-label clinical trials.

Labelling 64

Labelling Immunization 64

Hospital Pharmacy Europe

APRIL 23, 2024

It also marks the fourth marketing authorisation for the drug, adding to the existing indications in moderate-to-severe plaque psoriasis, active psoriatic arthritis and active axial spondyloarthritis. This approval makes bimekizumab the first biologic for moderate-to-severe HS to target IL-17F in addition to IL-17A.

Medical Schools 52

Medical Schools Hospitals 52

The Checkup by Singlecare

NOVEMBER 6, 2023

Those on immunosuppressive drugs for psoriasis or ulcerative colitis may soon breathe a little easier when they get to the pharmacy counter: The U.S. Manufactured by Amgen, the biosimilar—which is like a generic for biologic medications—was approved to treat inflammatory conditions like plaque psoriasis or ulcerative colitis.

FDA 110

FDA Immunization 110

PharmaShots

APRIL 17, 2023

Daniel Quirk: Psoriasis is a widely prevalent, chronic, systemic immune-mediated disease that affects approximately 7.5 Daniel Quirk: Psoriasis is a widely prevalent, chronic, systemic immune-mediated disease that affects approximately 7.5 million people in the United States. million people in the United States.

FDA 40

FDA Immunization Hospitals 40

pharmaphorum

JULY 19, 2021

During the last two decades, the landscape for psoriasis treatment has exploded. Suddenly, those with more severe psoriasis had safer and more effective treatment options that delivered the life-changing potential for clear skin. National Psoriasis Foundation found 52% of patients with psoriasis are dissatisfied with treatment.

58

58

European Pharmaceutical Review

APRIL 26, 2024

Recent biosimilar developments In February 2024, the EMA’s Committee for Medicinal Products for Human Use (CHMP) granted a positive opinion for Pyzchiva as a biosimilar to treat the autoimmune condition plaque psoriasis.

Packaging 52

Packaging Pharmaceutical Companies Pharmaceutical Companies FDA 52